Dear Friends,
As 2021 comes to a close, it’s time to reflect on a year filled with great hope as well as its challenges. The battle against COVID-19 continues, but thanks to your research, we now have vaccines and antivirals available. There are many other disease areas in which your research has been instrumental. These ongoing efforts provide all of us—healthcare organizations, life sciences companies, and most importantly patients—with the hope for an even more promising 2022. The entire TriNetX team is humbled and honored to be part of your continued success.
This is also the time of year to look back at what TriNetX and our community accomplished in 2021.
Most recently, we were thrilled to welcome Dr. Jeffrey Brown into the TriNetX family as our new Chief Scientific Officer. Jeff has worked with us for several years and taking on a full-time position provides us with an internationally-recognized expert in the application of real-world data to support the evidentiary needs of regulatory agencies, medical product sponsors, and collaborative research across healthcare organizations. His focus will be on working with you to expand the use of TriNetX’s rich real-world data assets.
Our Clinical Sciences & Operations division, consisting of PhDs, epidemiologists, clinical analysts, health economic and outcomes researchers, grew our support services in study design, feasibility, site identification, scientific communications, and the generation of real-world data sets and evidence for regulatory use. Amongst their many accomplishments this year, the team completed and delivered a regulatory-grade, real-world data chart review of COVID patients, analyzed more than 2,000 protocols, and helped our users navigate the data supporting more than 250 articles, out of which 121 were peer reviewed. The team also managed numerous clinical consulting engagements to help our customers better understand healthcare utilization, burden of illness, and clinical outcomes.
This year we launched TriNetX LINKED, which allows our partners to explore harmonized data across disparate, clinically rich data sources to gain a deeper understanding of the patient journey by linking de-identified electronic health records, closed payer claims data, and mortality data.
In November, TriNetX CONNECT replaced Trial Connect, with its data-driven focus on “the right trial, for the right patient, at the right site.” TriNetX CONNECT brings speed and transparency to the process of clinical trial site selection and onboarding. While study teams at both sponsors and healthcare organizations benefit greatly from the frictionless exchange, patients stand to gain the most, with more opportunity for trial participation and accelerated drug development.
Also in the spirit of making connections, we launched SiteIQ™ Plus. This offering arms study sponsors and CROs with even more data to guide their site selection decisions based on insights from our partnership with Advarra.
We are all acutely aware of the importance of diversity and inclusion—that a successful clinical trial cohort must be representative of the population it aims to treat, and there is much work to be done to make this a reality. We launched the TriNetX DIVERSITY LENS analytic to better equip investigators with the data and tools to bring equality to the forefront of trial design and site selection.
Our mission of improving patient lives is a global one. We have enhanced our Japan Claims Network for protocol design and feasibility analysis to include cohort location maps and a concierge service that connects study leaders with the 400+ acute care hospitals that have made their de-identified health data available on our platform. We’ve also welcomed new healthcare organizations throughout South America into our global research community, partnered with hospitals in Singapore and France, and continued to both broaden and deepen our relationships with healthcare organizations in many more countries and with healthcare data partners around the world.
As productive as 2021 has been, the year ahead promises even more.
-
- In January, we will launch the ability to perform rapid and robust pharmacovigilance signal detection, thanks to the combination of our global real-word data and novel technology to optimize signal management.
- In 2022, Clinical Sciences & Operations will continue to grow sponsor support services, chart reviews, feasibility analyses, and our investigation of new real-world data sources to better support market access strategies.
- TriNetX LINKED EHR with closed claims and mortality data will continue to grow in both the number of healthcare organizations participating and patient lives represented.
- Our HCO and industry partners will have the ability to apply their own scoring algorithms and statistical models to patients within our platform, turning the AI/ML promise into a reality for study cohort selection and evidence generation.
- TriNetX Global Oncology Network will launch in Spring 2022 with a focus on driving more oncology clinical trials to our HCO partners, letting you explore our rich set of cancer data, sourced and integrated from cancer registries, genomic databases, unstructured data from clinical notes and lab reports, and mortality data, right on our platform.
- We will support external control arms and cohort tagging so you can streamline multiple arm studies and follow patients over time as their real-world data on our platform continues to grow.
- TriNetX is eager to collaborate with you on ground-breaking publications, welcome new research partners and healthcare organizations from around the world, and, most importantly, support your work every day with the services and technology you have helped shape.
We continue to be grateful for your dedication and look forward to making even greater contributions to the health and welfare of patients around the world in 2022. To align our company’s vision of connecting the world to improve human health, the TriNetX team has made sizeable donations to the following charities on behalf of our global research community:
We thank you again and wish you and yours a happy and healthy holiday season.
Gadi
President and Chief Executive Officer
TriNetX, LLC